"All Comers" Post Market Clinical Follow-up (PMCF) With Multi-LOC for flOw liMiting Outcomes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

75 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-07-31

Study Completion Date

2017-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to assess the safety and efficacy of the Multi-LOC® peripheral stent system to treat de novo and restenotic lesions (no in-stent restenosis (ISR), no restenosis post drug coated balloon (DCB) after flow limiting plain old balloon angioplasty (POBA) and/or DCB dilatations in the superficial femoral artery (SFA) and popliteal segments (P1, P2 \& P3)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

"All Comers" Post Market Clinical Follow-up (PMCF) With Multi-LOC for flOw liMiting Outcomes (LOCOMOTIVE Extended)

NCT02900274

Peripheral Arterial Occlusive Disease

COMPLETED

A Post-Market Study of Drug-Coated Peripheral Balloon Dilatation Catheter in Treating Femoropopliteal Artery Stenosis or Occlusive Lesions.

NCT07187128

Femoropopliteal Artery Stenoses or Occlusive Lesions

NOT_YET_RECRUITING NA

Drug-Eluting Balloon Catheters and the Treatment of Peripheral Arterial Occlusive Disease

NCT01007578

Peripheral Arterial Disease Stenotic Femoro-popliteal Arteries Occluded Femoro-popliteal Arteries +1 more

COMPLETED PHASE1

Paclitaxel-coated Balloons in Femoral Indication to Defeat Restenosis

NCT01083030

Peripheral Artery Disease

COMPLETED PHASE3

BIOLUX P-I First in Man Study

NCT01221610

Atherosclerosis Arteriosclerosis Vascular Disease +1 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is an non-randomized, prospective, multi-center, non-interventional study (registry, for Germany: §23b MPG)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Arterial Occlusive Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VascuFlex Multi-LOC®

Multi-LOC® peripheral stent system for bailout stenting after Plain Old Balloon Angioplasty (POBA) or Drug Coated Balloon (DCB) Angioplasty

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Willingness to treat flow-limiting dissections/recoil after plain old balloon angioplasty (POBA)/drug coated balloon (DCB) interventions
* Patients in Rutherford classes 2 through 5
* Patients eligible for peripheral revascularization by means of percutaneous transluminal angioplasty (PTA) and stenting
* Patients must be at least 18 years of age
* Patient with a life expectance of at least 12 months
* Patients who are mentally and linguistically able to understand the aim of the study and to show sufficient compliance in the following study protocol
* Patients must agree to undergo at least the 6-month clinical follow-up
* Patient is able to verbally acknowledge an understanding of the associated risks, benefits, and treatment alternatives to therapeutic options of this trial, e.g. balloon angioplasty by means of other suitable stent devices. Patients, by providing their informed consent, agree to these risks and benefits as stated in the patient informed consent document.
* Lesions with unsatisfying angiographic results due to recoil and/or dissections after POBA/DCB interventions
* Infra-inguinal lesions in the superficial femoral artery (SFA) and popliteal segments (P1,P2 \& P3) reference vessel diameters between 4 and 7.0 mm, lesion length suitable for the release of at least 2 Stent (up to 6) segments implanted with a minimum inter-stent distance of 1 cm
* Diameter stenosis pre-procedure must be larger or equal to 70%
* Vessels must have adequate distal run-off with at least one vessel to the foot or with collaterals in the calf supplying sufficient flow to the foot.

(Lesions separated by less than 2 cm are considered as one lesion)